The stock of Zoetis Inc. (NYSE:ZTS) decreased by decreased by -$0.11 on Friday to finish at $208.51, down -0.05 percent. The last five days have seen an average of 903,680 shares of common stock traded. 40 times new highs were reached in the current year, with a gain of $43.01. The average number of shares traded over the last 20 days was 1,400,055, while the average volume over the last 50 days totaled 1,319,360.
ZTS stock appreciated 1.86% since last month. On 10/04/21, the company’s shares reached a one-month low of $190.93. The stock touched a high of $210.10 on 09/03/21, after rallying from a low of $141.41 in 52 weeks. The price of ZTS stock has risen by 25.99% or $43.01 this year, reaching a new high 40 times. Still, the stock price is down -0.76% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 3 days since Zoetis Inc. (ZTS) last reported insider trading activity on Oct 22. On Oct 22, Executive Vice President Lagano Roxanne sold 1,315 shares at $208.03 each. This transaction resulted in the insider making $273,559. On Oct 01, Trawicki Roman sold 4,497 shares at a price of US$194.14. After the transaction, the insider now owns 0 shares. Executive Vice President Lagano Roxanne had earlier sold 1,315 shares on Sep 23 for $202.17 a share. The transaction was completed for $265,854.
Zoetis Inc. (ZTS) has a trailing price-to-earnings (P/E) ratio of 52.21. This level actually compares unfavorably with the industry at large, as the PE for the Drug Manufacturers – Specialty & Generic industry stands at about 37.29. Further, its PE also compares unfavorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Zoetis Inc. has varied between 52.55 and 27.84 in the last five years. Beta for the stock is 0.64. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 13.34, the price-to-book (PB) ratio of 22.76, and the price-to-cash flow ratio of 77.61.
Zoetis Inc.’s dividend is $1.00 per share per year. With a dividend yield of 0.48%, ZTS has a payout ratio of 22.40%. Company paid $0.25 per share in dividends, remained unchanged from $0.25 last year. A $0.05 dividend increase was reported on Wednesday December 9 2020, making it the 1 consecutive year the dividend has increased.
For the three months ended June 29, Zoetis Inc.’s quick ratio was 2.50, while its current ratio was 3.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.52, and the total debt to equity ratio is 1.65. As far as profitability goes, gross margin for the trailing twelve months is 69.70% percent. Zoetis Inc.’s operating margin stood at 31.60% for the same period. Based on annual data, it had gross profit of $4.62 billion and revenue of $6.67 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ZTS’s return on assets (ROA) during the last 12 months has been 13.80%. There was a 14.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 48.30%. ROE has averaged -15.50 in the past year for the broader industry.
According to Zoetis Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.95 billion, while revenues rose by 20.53% to $1.87 billion. It was predicted that Zoetis Inc.’s quarterly earnings would be $1.19, but it ended up being $1.08, beating the consensus by 10.20%. EBITDA was $805.0 million for the quarter. At the end of Zoetis Inc.’s most recent quarter ended June 29, its liabilities totaled 9.72 billion, while its total debt was $7.35 billion. Equity owned by shareholders amounts to $473.94 million.
Here’s a quick look at Zoetis Inc.’s (ZTS) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 75.27%, suggesting the stock is Overbought, with a 7.30% historical volatility rate.
The stochastic %K and %D were 97.86% and 96.05% respectively, while the average true range (ATR) was 3.37. Based on the 14-day stochastic reading of 96.39%, the RSI (14) reading is 66.08%. On the 9-day MACD Oscillator, the stock is at 4.72, and the 14-day reading is at 6.77.
Analysts have assigned Zoetis Inc. (ZTS) an Overweight rating. ZTS is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 3 rates it overweight and 10 others recommend it as a buy.
What is ZTS’s price target for the next 12 months?
The current consensus forecast for the stock is between $184.00 and $240.00, with a median target price of $227.00. In analyzing these forecasts, the average price target given by analysts for Zoetis Inc. (ZTS) is $225.00.